208655-19-0

Basic information

• Product Name: Piperazine, 2-(phenylmethyl)-, (2S)- (9CI)
• Synonyms: Piperazine, 2-(phenylmethyl)-, (2S)- (9CI);(2S)-2-BENZYLPIPERAZINE;2(S)-Benzylpiperazine;Piperazine, 2-(phenylmethyl)-, (2S)-;(S)-2-BENZYL-PIPERAZINE 2HCl;(2S)-2-(Phenylmethyl)-piperazine;(S)-2-Benzylpiperazinedihydrochloride
• CAS NO: 208655-19-0
• Molecular Formula: C₁₁H₁₆N₂
• Molecular Weight: 176.25814
• Product Categories: PIPERIDINE
• Mol File: 208655-19-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 293°C at 760 mmHg
• Flash Point: 165.8°C
• Appearance: /
• Density: 0.996g/cm³
• Vapor Pressure: 0.00178mmHg at 25°C
• Refractive Index: 1.526
• PKA: 9.25±0.40(Predicted)
• CAS DataBase Reference: Piperazine, 2-(phenylmethyl)-, (2S)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Piperazine, 2-(phenylmethyl)-, (2S)- (9CI)(208655-19-0)
• EPA Substance Registry System: Piperazine, 2-(phenylmethyl)-, (2S)- (9CI)(208655-19-0)

Safety Data

• Hazardous Substances Data: 208655-19-0(Hazardous Substances Data)

Usage

General Description

Piperazine, 2-(phenylmethyl)-, (2S)- (9CI) is a chemical compound with the molecular formula C11H16N2. It is a derivative of piperazine, a heterocyclic organic compound commonly used in the pharmaceutical industry. The (2S)- enantiomer of this compound is a chiral form, meaning it has a non-superimposable mirror image. This chemical may have potential applications in medicinal chemistry, particularly in the development of pharmaceutical drugs and drug discovery. However, further research is needed to fully understand its properties and potential uses.

InChI:InChI=1/C11H16N2/c1-2-4-10(5-3-1)8-11-9-12-6-7-13-11/h1-5,11-13H,6-9H2/t11-/m0/s1

Upstream product

• 5037-75-2 cyclo(Gly-Phe) 

Downstream Products

• 1354376-46-7 C₁₄H₁₉N₃ 
• 1064651-76-8 5-(3(S)-benzyl-piperazin-1-yl)-8-(2-naphthyl)-7-(pyridin-4-yl)-1,2,4-triazolo[4,3-c]pyrimidine 
• 942123-11-7 3-(S)-benzyl-1-(4-bromo-benzyl)-piperazine 
• 848553-41-3 10-(S)-(3-benzylpiperazin-1-yl)-2-methyl-4H-3-thia-9-azabenzo[f]azulene 
• 1308375-51-0 3-((R)-2-amino-2-phenylethyl)-5-((S)-3-benzylpiperazin-1-yl)-1-(2,6-difluorobenzyl)-6-methylpyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

Histone demethylase LSD1 (lysine specific demethylase 1) inhibitor

The invention provides a histone demethylase LSD1 (lysine specific demethylase 1) inhibitor. The invention relates to piperazine-containing compounds and pharmacologically acceptable salts thereof and use of the piperazine-containing compounds and pharmacologically acceptable salts thereof as the LSD1 inhibitor; the general structural formula of the piperazine-containing compounds is described in the description. The invention belongs to the field of pharmaceutical chemistry. An in-vitro LSD1 activity inhibition test proves that the piperazine-containing compounds implemented by the invention have an obvious inhibiting effect for LSD1 activity, thus being used as active ingredients for preparing LSD1 inhibitor medicines.

SUBSTITUTED PIPERAZINES OF AZEPINES, OXAZEPINES, AND THIAZEPINES

Described herein are antipyschotic compounds of formula (I) wherein: is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; R1 is hydrogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, or (C1-4) alkyl, wherein the (C1-4) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH2CH2OH, -CN, imidazolidin-2-one, phenyl, or tetrazole wherein tetrazole is unsubstituted or substituted with (C1-4) alkyl; R2 is H, halogen, (C1-6) fluoroalkyl, (C3-6) cycloalkyl, OR6, SR6, NO2, CN, COR6, C(O)OR6, C(OH)R6, CONR7R8, phenyl or (C1-6) alkyl, wherein the (C1-6) alkyl is unsubstituted or substituted with a hydroxy; R3 is hydrogen, (C 1-6)fluoroalkyl , (C3-6) cycloalkyl, (C2-6) alkenyl, phenyl, monocyclic heteroaromatic, bicyclic heteroaromatic, or (C1-4)alkyl wherein (C1-4) alkyl is unsubstituted or substituted with a phenyl; R4 and R5 are independently selected from hydrogen, halogen, (C1-6) alkyl, (C1-6) fluoroalkyl, OR9, SR9, NO2, CN, or COR9; R6 is hydrogen, (C1-6) fluoroalkyl, or (C1-6) alkyl; R7 and R8 are independently hydrogen, or (C1-6) alkyl; R9 is hydrogen, (C1-6) fluoroalkyl, (C1-6) alkyl; Alk is (C1-4) alkylene unsubstituted or substituted with a hydroxy; Y is oxygen, sulfur, SO2, or a bond; X is CH2, C=O, S, O, or SO2; Z is hydrogen, halogen, (C1-6) alkyl, (C1-6)fluoroalkyl, -OH, (C1-6) alkoxy, (C1-6) fluoroalkoxy, (C1-6) alkylthio, (C1-6) acyl, (C1-4)alkylsulfonyl, -OCF3, -NO2, - CN, carboxamido which may be substituted on the nitrogen by one or two (C1-4) alkyl groups, and -NH2 in which one of the hydrogens may be replaced by a (C1-4) alkyl group and the other hydrogen may be replaced by either a (C1-4) alkyl group, a (C1-6) acyl group, or a (C1-4) alkylsulfonyl group; the phenyl of R1, R2 or R3 is independently unsubstituted or substituted with one to three substituents independently selected from Z; the monocyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; the bicyclic heteroaromatic of R3 is unsubstituted or substituted with one to three substituents independently selected from Z; and salts, solvates, and crystal forms thereof. Also described are the use of the compounds of formula (I) as antagonists of the dopamine D2 receptor and as agents for the treatment of psychosis and bipolar disorders, and pharmaceutical formulations of the compounds of formula (I).

PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS

Described herein are antipyschotic compounds of formula (I) wherein, A is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, O, and S; Alk is (C1-4) alkylene optionally substituted w